| 1. Martin GE, Elgin RJ, Mathiasen JR, Davis CB, Kesslick JM, Baldy WJ, Shank RP, DiStefano DL, Fedde CL, Scott MK.. (1989) Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy., 32 (5): [PMID:2565400] [10.1021/jm00125a020] |
| 2. Showell GA, Gibbons TL, Kneen CO, MacLeod AM, Merchant K, Saunders J, Freedman SB, Patel S, Baker R.. (1991) Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands., 34 (3): [PMID:2002451] [10.1021/jm00107a032] |
| 3. Rzeszotarski WJ, Gibson RE, Eckelman WC, Simms DA, Jagoda EM, Ferreira NL, Reba RC.. (1982) Analogues of 3-quinuclidinyl benzilate., 25 (9): [PMID:7131491] [10.1021/jm00351a020] |
| 4. Sowell JW, Tang Y, Valli MJ, Chapman JM, Usher LA, Vaughan CM, Kosh JW.. (1992) Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine., 35 (6): [PMID:1552502] [10.1021/jm00084a015] |
| 5. Saunders J, Cassidy M, Freedman SB, Harley EA, Iversen LL, Kneen C, MacLeod AM, Merchant KJ, Snow RJ, Baker R.. (1990) Novel quinuclidine-based ligands for the muscarinic cholinergic receptor., 33 (4): [PMID:2319559] [10.1021/jm00166a008] |
| 6. Jorgensen WL, Duffy EM.. (2000) Prediction of drug solubility from Monte Carlo simulations., 10 (11): [PMID:10866370] [10.1016/s0960-894x(00)00172-4] |
| 7. Lombardo F, Obach RS, Shalaeva MY, Gao F.. (2004) Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics., 47 (5): [PMID:14971904] [10.1021/jm030408h] |
| 8. Sloan JW, Martin WR, Hook R, Hernandez J.. (1985) Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation., 28 (9): [PMID:4032427] [10.1021/jm00147a021] |
| 9. Carroll FI, Abraham P, Mascarella SW, Singh P, Moreland CG, Sankar SS, Kwon YW, Triggle DJ.. (1991) Crystal, solution, and molecular modeling structural properties and muscarinic antagonist activity of azaprophen., 34 (4): [PMID:2016720] [10.1021/jm00108a030] |
| 10. Rzeszotarski WJ, McPherson DW, Ferkany JW, Kinnier WJ, Noronha-Blob L, Kirkien-Rzeszotarski A.. (1988) Affinity and selectivity of the optical isomers of 3-quinuclidinyl benzilate and related muscarinic antagonists., 31 (7): [PMID:3385735] [10.1021/jm00402a035] |
| 11. Leader H, Smejkal RM, Payne CS, Padilla FN, Doctor BP, Gordon RK, Chiang PK.. (1989) Binary antidotes for organophosphate poisoning: aprophen analogues that are both antimuscarinics and carbamates., 32 (7): [PMID:2738887] [10.1021/jm00127a020] |
| 12. Andrews PR, Craik DJ, Martin JL.. (1984) Functional group contributions to drug-receptor interactions., 27 (12): [PMID:6094812] [10.1021/jm00378a021] |
| 13. Romanelli MN, Teodori E, Gualtieri F, Angeli P, Brasili L.. (1988) Enantioselectivity of muscarinic antagonists. 2,2-Dicyclohexyl-5-[(dimethylamino)methyl]-1,3-oxathiolane methiodides and related 3-oxides., 31 (9): [PMID:3411598] [10.1021/jm00117a006] |
| 14. Romanelli MN, Gualtieri F, Valle G, Brasili L, Angeli P.. (1988) Enantioselectivity of muscarinic antagonists. Isomeric 2-cyclohexyl-2-phenyl-5-[(dimethylamino)methyl]-1,3-oxathiolane methiodides., 31 (9): [PMID:3411599] [10.1021/jm00117a007] |
| 15. Gualtieri F, Conti G, Dei S, Giovannoni MP, Nannucci F, Romanelli MN, Scapecchi S, Teodori E, Fanfani L, Ghelardini C.. (1994) Presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs. 1. Tropic and 2-phenylpropionic acid esters., 37 (11): [PMID:8201605] [10.1021/jm00037a022] |
| 16. Amstutz R, Ringdahl B, Karlén B, Roch M, Jenden DJ.. (1985) Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones., 28 (12): [PMID:2933518] [10.1021/jm00150a004] |
| 17. Atkinson ER, McRitchie-Ticknor DD, Harris LS, Archer S, Aceto MD, Pearl J, Luduena FP.. (1983) Parasympatholytic (anticholinergic) esters of the isomeric 2-tropanols. 2. Non-glycolates., 26 (12): [PMID:6644747] [10.1021/jm00366a023] |
| 18. Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D, Koyama F, Matsumoto K, Moriyama T, Yamamoto LT, Watanabe K, Murayama T, Horie S.. (2002) Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands., 45 (9): [PMID:11960505] [10.1021/jm010576e] |
| 19. Melchiorre C, Cassinelli A, Quaglia W.. (1987) Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors., 30 (1): [PMID:3806594] [10.1021/jm00384a034] |
| 20. MacLeod AM, Baker R, Freedman SB, Patel S, Merchant KJ, Roe M, Saunders J.. (1990) Synthesis and muscarinic activities of 1,2,4-thiadiazoles., 33 (7): [PMID:2362286] [10.1021/jm00169a041] |
| 21. Cereda E, Ezhaya A, Gil Quintero M, Bellora E, Dubini E, Micheletti R, Schiavone A, Brambilla A, Schiavi GB, Donetti A.. (1990) Synthesis and biological evaluation of new antimuscarinic compounds with amidine basic centers. A useful bioisosteric replacement of classical cationic heads., 33 (8): [PMID:2374141] [10.1021/jm00170a010] |
| 22. Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE.. (1998) Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity., 41 (12): [PMID:9622555] [10.1021/jm980076u] |
| 23. Carroll FI, Abraham P, Chemburkar S, He XC, Mascarella SW, Kwon YW, Triggle DJ.. (1992) Synthesis and muscarinic receptor activity of ester derivatives of 2-substituted 2-azabicyclo[2.2.1]heptan-5-ol and -6-ol., 35 (12): [PMID:1613746] [10.1021/jm00090a006] |
| 24. Chumpradit S, Kung MP, Billings J, Mach R, Kung HF.. (1993) Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT., 36 (2): [PMID:8093734] [10.1021/jm00054a005] |
| 25. Calderon SN, Izenwasser S, Heller B, Gutkind JS, Mattson MV, Su TP, Newman AH.. (1994) Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma 1 ligands., 37 (15): [PMID:8057277] [10.1021/jm00041a006] |
| 26. Lombardo F, Shalaeva MY, Tupper KA, Gao F.. (2001) ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds., 44 (15): [PMID:11448232] [10.1021/jm0100990] |
| 27. Yoshida F, Topliss JG.. (2000) QSAR model for drug human oral bioavailability., 43 (13): [PMID:10891117] [10.1021/jm0000564] |
| 28. Street LJ, Baker R, Book T, Kneen CO, MacLeod AM, Merchant KJ, Showell GA, Saunders J, Herbert RH, Freedman SB.. (1990) Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors., 33 (10): [PMID:2213823] [10.1021/jm00172a003] |
| 29. Lu MC, Wung WE, Shih LB, Callejas S, Gearien JE, Thompson EB.. (1987) Molecular modification of anticholinergics as probes for muscarinic receptors. 1. Amino esters of alpha-substituted phenylacetic acid and related analogues., 30 (2): [PMID:3806612] [10.1021/jm00385a008] |
| 30. Lombardo F, Obach RS, Shalaeva MY, Gao F.. (2002) Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data., 45 (13): [PMID:12061889] [10.1021/jm0200409] |
| 31. Nilsson BM, Vargas HM, Ringdahl B, Hacksell U.. (1992) Phenyl-substituted analogues of oxotremorine as muscarinic antagonists., 35 (2): [PMID:1732545] [10.1021/jm00080a013] |
| 32. Hudkins RL, DeHaven-Hudkins DL, Stubbins JF.. (1991) Muscarinic receptor binding profile of para-substituted caramiphen analogues., 34 (10): [PMID:1920350] [10.1021/jm00114a005] |
| 33. Street LJ, Baker R, Book T, Reeve AJ, Saunders J, Willson T, Marwood RS, Patel S, Freedman SB.. (1992) Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives., 35 (2): [PMID:1732546] [10.1021/jm00080a014] |
| 34. Bucholtz EC, Brown RL, Tropsha A, Booth RG, Wyrick SD.. (1999) Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors., 42 (16): [PMID:10447948] [10.1021/jm980428x] |
| 35. Audia VH, McPherson DW, Weitzberg M, Rzeszotarski WJ, Sturm B, Kachur JF, Abreu M, Kaiser C.. (1990) Synthesis of some 3-(1-azabicyclo[2.2.2]octyl) 3-amino-2-hydroxy-2-phenylpropionates: profile of antimuscarinic efficacy and selectivity., 33 (1): [PMID:2296026] [10.1021/jm00163a050] |
| 36. Valli MJ, Tang Y, Kosh JW, Chapman JM, Sowell JW.. (1992) Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethylamino analogs of ranitidine., 35 (17): [PMID:1507203] [10.1021/jm00095a008] |
| 37. Zhuang ZP, Kung MP, Kung HF.. (1993) Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand., 36 (21): [PMID:8230102] [10.1021/jm00073a016] |
| 38. Triggle DJ, Kwon YW, Abraham P, Pitner JB, Mascarella SW, Carroll FI.. (1991) Synthesis, molecular modeling studies, and muscarinic receptor activity of azaprophen analogues., 34 (11): [PMID:1956033] [10.1021/jm00115a003] |
| 39. Lundkvist JR, Vargas HM, Caldirola P, Ringdahl B, Hacksell U.. (1990) Resolved pyrrolidine, piperidine, and perhydroazepine analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide., 33 (12): [PMID:2258904] [10.1021/jm00174a014] |
| 40. Xu R, Sim MK, Go ML.. (1998) Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists., 41 (17): [PMID:9703467] [10.1021/jm9708588] |
| 41. Johansson G, Sundquist S, Nordvall G, Nilsson BM, Brisander M, Nilvebrant L, Hacksell U.. (1997) Antimuscarinic 3-(2-furanyl)quinuclidin-2-ene derivatives: synthesis and structure-activity relationships., 40 (23): [PMID:9371246] [10.1021/jm970346t] |
| 42. McNeal ET, Lewandowski GA, Daly JW, Creveling CR.. (1985) [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs., 28 (3): [PMID:2579237] [10.1021/jm00381a019] |
| 43. Melchiorre C, Bolognesi ML, Budriesi R, Ghelardini C, Chiarini A, Minarini A, Rosini M, Tumiatti V, Wade EJ.. (2001) Design, synthesis, and biological activity of methoctramine-related polyamines as putative G(i) protein activators., 44 (24): [PMID:11708906] [10.1021/jm0155594] |
| 44. Lu MC, Shih LB, Jae HS, Gearien JE, Thompson EB.. (1987) Molecular modification of anticholinergics as probes for muscarinic receptors. 2. Amino esters of alpha-methyltropic acid., 30 (2): [PMID:3806623] [10.1021/jm00385a028] |
| 45. Kaiser C, Spagnuolo CJ, Adams TC, Audia VH, Dupont AC, Hatoum H, Lowe VC, Prosser JC, Sturm BL, Noronha-Blob L.. (1992) Synthesis and antimuscarinic properties of some N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones., 35 (23): [PMID:1447741] [10.1021/jm00101a019] |
| 46. Saunders J, Showell GA, Snow RJ, Baker R, Harley EA, Freedman SB.. (1988) 2-Methyl-1,3-dioxaazaspiro[4.5]decanes as novel muscarinic cholinergic agonists., 31 (2): [PMID:3339620] [10.1021/jm00397a039] |
| 47. Scott MK, Jacoby HI, Mills JE, Bonfilio AC, Rasmussen CR.. (1983) 4-(Diphenylmethyl)-1-[(imino)methyl]piperidines as gastric antisecretory agents., 26 (4): [PMID:6834385] [10.1021/jm00358a014] |
| 48. Mitch CH, Brown TJ, Bymaster FP, Calligaro DO, Dieckman D, Merrit L, Peters SC, Quimby SJ, Shannon HE, Shipley LA, Ward JS, Hansen K, Olesen PH, Sauerberg P, Sheardown MJ, Swedberg MD, Suzdak P, Greenwood B.. (1997) Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome., 40 (4): [PMID:9046345] [10.1021/jm9602470] |
| 49. Lüllmann H, Timmermans PB, Weikert GM, Ziegler A.. (1980) Accumulation of drugs by guinea pig isolated atria. Quantitative correlations., 23 (5): [PMID:7381857] [10.1021/jm00179a017] |
| 50. Kaiser C, Audia VH, Carter JP, McPherson DW, Waid PP, Lowe VC, Noronha-Blob L.. (1993) Synthesis and antimuscarinic activity of some 1-cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and related compounds., 36 (5): [PMID:8496940] [10.1021/jm00057a010] |
| 51. Elz S, Heil WL. (1995) Synthesis, biological in vitro evaluation and stereoselectivity of ondansetron analogues: novel 5-HT2A receptor antagonists, 5 (7): [10.1016/0960-894X(95)00092-8] |
| 52. Ringdahl B.. (1988) 5-Methyl-2-pyrrolidone analogues of oxotremorine as selective muscarinic agonists., 31 (3): [PMID:3346881] [10.1021/jm00398a031] |
| 53. Connor DT, Unangst PC, Schwender CF, Sorenson RJ, Carethers ME, Puchalski C, Brown RE, Finkel MP.. (1989) 3-(aminoalkyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c] pyridin-5-ones as potential anticholinergic bronchodilators., 32 (3): [PMID:2645403] [10.1021/jm00123a032] |
| 54. Carroll FI, Abraham P, Parham K, Griffith RC, Ahmad A, Richard MM, Padilla FN, Witkin JM, Chiang PK.. (1987) 6-Methyl-6-azabicyclo[3.2.1]octan-3 alpha-ol 2,2-diphenylpropionate (azaprophen), a highly potent antimuscarinic agent., 30 (5): [PMID:3494849] [10.1021/jm00388a010] |
| 55. Melchiorre C, Quaglia W, Picchio MT, Giardinà D, Brasili L, Angeli P.. (1989) Structure-activity relationships among methoctramine-related polymethylene tetraamines. Chain-length and substituent effects on M-2 muscarinic receptor blocking activity., 32 (1): [PMID:2909747] [10.1021/jm00121a017] |
| 56. McPherson DW, DeHaven-Hudkins DL, Callahan AP, Knapp FF.. (1993) Synthesis and biodistribution of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate. A new ligand for the potential imaging of muscarinic receptors by single photon emission computed tomography., 36 (7): [PMID:8464039] [10.1021/jm00059a009] |
| 57. Oliver DW, Dekker TG, Snyckers FO, Fourie TG.. (1991) Synthesis and biological activity of D3-trishomocubyl-4-amines., 34 (2): [PMID:1995908] [10.1021/jm00106a053] |
| 58. Lundkvist JR, Ringdahl B, Hacksell U.. (1989) Conformationally restricted analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide., 32 (4): [PMID:2704032] [10.1021/jm00124a022] |
| 59. Martin AR, Paradkar VM, Peng GW, Speth RC, Yamamura HI, Horn AS.. (1980) Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues., 23 (8): [PMID:6249933] [10.1021/jm00182a011] |
| 60. Scott MK, Jacoby HI, Bonfilio AC, Corcoran TW, Lopez IS.. (1987) Antisecretory activity of human, dog, and rat metabolites of fenoctimine., 30 (5): [PMID:3572978] [10.1021/jm00388a025] |
| 61. Leader H, Wolfe AD, Chiang PK, Gordon RK.. (2002) Pyridophens: binary pyridostigmine-aprophen prodrugs with differential inhibition of acetylcholinesterase, butyrylcholinesterase, and muscarinic receptors., 45 (4): [PMID:11831902] [10.1021/jm010196t] |
| 62. Showell GA, Baker R, Davis J, Hargreaves R, Freedman SB, Hoogsteen K, Patel S, Snow RJ.. (1992) Synthesis and in vitro biological profile of all four isomers of the potent muscarinic agonist 3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane., 35 (5): [PMID:1548680] [10.1021/jm00083a016] |
| 63. Sagara Y, Sagara T, Mase T, Kimura T, Numazawa T, Fujikawa T, Noguchi K, Ohtake N.. (2002) Cyclohexylmethylpiperidinyltriphenylpropioamide: a selective muscarinic M(3) antagonist discriminating against the other receptor subtypes., 45 (4): [PMID:11831911] [10.1021/jm010480k] |
| 64. Tumiatti V, Minarini A, Milelli A, Rosini M, Buccioni M, Marucci G, Ghelardini C, Bellucci C, Melchiorre C.. (2007) Structure-activity relationships of methoctramine-related polyamines as muscarinic antagonist: effect of replacing the inner polymethylene chain with cyclic moieties., 15 (6): [PMID:17276075] [10.1016/j.bmc.2007.01.022] |
| 65. Baert B, Deconinck E, Van Gele M, Slodicka M, Stoppie P, Bodé S, Slegers G, Vander Heyden Y, Lambert J, Beetens J, De Spiegeleer B.. (2007) Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds., 15 (22): [PMID:17827020] [10.1016/j.bmc.2007.07.050] |
| 66. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E.. (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model., 51 (2): [PMID:18027916] [10.1021/jm070524a] |
| 67. Towers GH, Abramowski Z.. (1983) UV-mediated genotoxicity of furanoquinoline and of certain tryptophan-derived alkaloids., 46 (4): [PMID:6195312] [10.1021/np50028a027] |
| 68. Bifulco G, Bruno I, Minale L, Riccio R, Calignano A, Debitus C.. (1994) (+/-)-Gelliusines A and B, two diastereomeric brominated tris-indole alkaloids from a deep water new caledonian marine sponge (Gellius or Orina sp.)., 57 (9): [PMID:7798965] [10.1021/np50111a020] |
| 69. Ustünes L, Laekeman GM, Gözler B, Vlietinck AJ, Ozer A, Herman AG.. (1988) In vitro study of the anticholinergic and antihistaminic activities of protopine and some derivatives., 51 (5): [PMID:2904975] [10.1021/np50059a043] |
| 70. Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.. (2008) Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors., 51 (21): [PMID:18834112] [10.1021/jm800656v] |
| 71. Wan H, Ahman M, Holmén AG.. (2009) Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs., 52 (6): [PMID:19256501] [10.1021/jm801441s] |
| 72. Bard B, Carrupt PA, Martel S.. (2009) Lipophilicity of basic drugs measured by hydrophilic interaction chromatography., 52 (10): [PMID:19397318] [10.1021/jm9003945] |
| 73. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.. (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1., 51 (19): [PMID:18788725] [10.1021/jm8003152] |
| 74. Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR, Plumley HC, Weaver CD, Conn PJ, Lindsley CW.. (2009) Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins., 52 (11): [PMID:19438238] [10.1021/jm900286j] |
| 75. Mok SL, Yoganathan K, Lim TM, Kam TS.. (1998) Cardiovascular effects of aspidofractinine-type alkaloids from Kopsia., 61 (3): [PMID:9544563] [10.1021/np9703712] |
| 76. Sweetnam PM, Caldwell L, Lancaster J, Bauer C, McMillan B, Kinnier WJ, Price CH.. (1993) The role of receptor binding in drug discovery., 56 (4): [PMID:8496700] [10.1021/np50094a001] |
| 77. Huss U, Ringbom T, Perera P, Bohlin L, Vasänge M.. (2002) Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay., 65 (11): [PMID:12444669] [10.1021/np020023m] |
| 78. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.. (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)., 51 (11): [PMID:18457386] [10.1021/jm7015683] |
| 79. Li JH, Han SJ, Hamdan FF, Kim SK, Jacobson KA, Bloodworth LM, Zhang X, Wess J.. (2007) Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands., 282 (36): [PMID:17623649] [10.1074/jbc.m704875200] |
| 80. Alimuddin M, Grant D, Bulloch D, Lee N, Peacock M, Dahl R.. (2008) Determination of log D via automated microfluidic liquid-liquid extraction., 51 (16): [PMID:18666772] [10.1021/jm8005228] |
| 81. Gilligan PJ, Clarke T, He L, Lelas S, Li YW, Heman K, Fitzgerald L, Miller K, Zhang G, Marshall A, Krause C, McElroy JF, Ward K, Zeller K, Wong H, Bai S, Saye J, Grossman S, Zaczek R, Arneric SP, Hartig P, Robertson D, Trainor G.. (2009) Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists., 52 (9): [PMID:19361209] [10.1021/jm900025h] |
| 82. Verma SM, Razdan BK, Sasmal D.. (2009) 3D-QSAR study of 8-azabicyclo[3.2.1] octane analogs antagonists of cholinergic receptor., 19 (11): [PMID:19419864] [10.1016/j.bmcl.2009.03.164] |
| 83. Bhattacharjee AK, Gordon JA, Marek E, Campbell A, Gordon RK.. (2009) 3D-QSAR studies of 2,2-diphenylpropionates to aid discovery of novel potent muscarinic antagonists., 17 (11): [PMID:19409797] [10.1016/j.bmc.2009.04.001] |
| 84. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.. (2009) Physicochemical determinants of human renal clearance., 52 (15): [PMID:19445515] [10.1021/jm900403j] |
| 85. Bhattacharjee AK, Gordon JA, Marek E, Campbell A, Gordon RK.. (2009) 3D-QSAR studies of 2,2-diphenylpropionates to aid discovery of novel potent muscarinic antagonists., 17 (11): [PMID:19409797] [10.1016/j.bmc.2009.04.001] |
| 86. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.. (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination., 53 (3): [PMID:20070106] [10.1021/jm901371v] |
| 87. Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.. (2009) Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data., 44 (11): [PMID:19586686] [10.1016/j.ejmech.2009.06.004] |
| 88. Tasso B, Budriesi R, Vazzana I, Ioan P, Micucci M, Novelli F, Tonelli M, Sparatore A, Chiarini A, Sparatore F.. (2010) Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation., 53 (12): [PMID:20509610] [10.1021/jm100298d] |
| 89. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ.. (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission., 4 (1): [PMID:18059262] [10.1038/nchembio.2007.55] |
| 90. Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068] |
| 91. Kokel D, Bryan J, Laggner C, White R, Cheung CY, Mateus R, Healey D, Kim S, Werdich AA, Haggarty SJ, Macrae CA, Shoichet B, Peterson RT.. (2010) Rapid behavior-based identification of neuroactive small molecules in the zebrafish., 6 (3): [PMID:20081854] [10.1038/nchembio.307] |
| 92. Sams AG, Hentzer M, Mikkelsen GK, Larsen K, Bundgaard C, Plath N, Christoffersen CT, Bang-Andersen B.. (2010) Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential., 53 (17): [PMID:20684563] [10.1021/jm100697g] |
| 93. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 94. Hayashi S, Nakata E, Morita A, Mizuno K, Yamamura K, Kato A, Ohashi K.. (2010) Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships., 18 (21): [PMID:20875743] [10.1016/j.bmc.2010.07.034] |
| 95. Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.. (2011) Prediction of drug intestinal absorption by new linear and non-linear QSPR., 46 (1): [PMID:21112128] [10.1016/j.ejmech.2010.11.005] |
| 96. Lowe R, Glen RC, Mitchell JB.. (2010) Predicting phospholipidosis using machine learning., 7 (5): [PMID:20799726] [10.1021/mp100103e] |
| 97. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 98. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.. (2008) Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models., 18 (2): [PMID:20020916] [10.1080/15376510701857262] |
| 99. Unpublished dataset, |
| 100. Lebar MD, Hahn KN, Mutka T, Maignan P, McClintock JB, Amsler CD, van Olphen A, Kyle DE, Baker BJ.. (2011) CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs., 19 (19): [PMID:21907583] [10.1016/j.bmc.2011.08.033] |
| 101. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 102. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007] |
| 103. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 104. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 105. Poslusney MS, Sevel C, Utley TJ, Bridges TM, Morrison RD, Kett NR, Sheffler DJ, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR.. (2012) Synthesis and biological characterization of a series of novel diaryl amide M₁ antagonists., 22 (22): [PMID:23062550] [10.1016/j.bmcl.2012.09.011] |
| 106. Daval SB, Valant C, Bonnet D, Kellenberger E, Hibert M, Galzi JL, Ilien B.. (2012) Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors., 55 (5): [PMID:22329602] [10.1021/jm201348t] |
| 107. Ramirez-Galicia G, Martinez-Pacheco H, Garduno-Juarez R, Deeb O. (2012) Exploring QSAR of antiamoebic agents of isolated natural products by MLR, ANN, and RTO, 21 (9): [10.1007/s00044-011-9767-1] |
| 108. Toyomura N, Kuwano E.. (1998) Effect of tropine derivatives, antimuscarinic agents, on the growth of Bombyx mori larvae., 62 (10): [PMID:9836442] [10.1271/bbb.62.2046] |
| 109. TOMIZAWA M, YAMAMOTO I. (1992) Binding of Nicotinoids and the Related Compounds to the Insect Nicotinic Acetyicholine Receptor, 17 (4): [10.1584/jpestics.17.4_231] |
| 110. Muhi-eldeen Z, Al-Kaissi E, Ghantous H. (2013) Synthesis and biological evaluation of N 1,N 2-bis-[4-(t-amino)-2-butynyl]phthalamides as oxotremorine and acetylcholine antagonists, 22 (4): [10.1007/s00044-012-0147-2] |
| 111. Sheffler DJ, Sevel C, Le U, Lovell KM, Tarr JC, Carrington SJ, Cho HP, Digby GJ, Niswender CM, Conn PJ, Hopkins CR, Wood MR, Lindsley CW.. (2013) Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism., 23 (1): [PMID:23200253] [10.1016/j.bmcl.2012.10.132] |
| 112. Bhattacharjee AK, Pomponio JW, Evans SA, Pervitsky D, Gordon RK.. (2013) Discovery of subtype selective muscarinic receptor antagonists as alternatives to atropine using in silico pharmacophore modeling and virtual screening methods., 21 (9): [PMID:23523385] [10.1016/j.bmc.2013.01.072] |
| 113. Bhattacharjee AK, Pomponio JW, Evans SA, Pervitsky D, Gordon RK.. (2013) Discovery of subtype selective muscarinic receptor antagonists as alternatives to atropine using in silico pharmacophore modeling and virtual screening methods., 21 (9): [PMID:23523385] [10.1016/j.bmc.2013.01.072] |
| 114. Settimo L, Bellman K, Knegtel RM.. (2013) Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds., [PMID:24249037] [10.1007/s11095-013-1232-z] |
| 115. Settimo L, Bellman K, Knegtel RM.. (2013) Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds., [PMID:24249037] [10.1007/s11095-013-1232-z] |
| 116. PubChem BioAssay data set, |
| 117. PubChem BioAssay data set, |
| 118. PubChem BioAssay data set, |
| 119. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 120. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 121. Gentry PR, Kokubo M, Bridges TM, Noetzel MJ, Cho HP, Lamsal A, Smith E, Chase P, Hodder PS, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR.. (2014) Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)., 57 (18): [PMID:25147929] [10.1021/jm500995y] |
| 122. PubChem BioAssay data set, |
| 123. Roman BI, De Ryck T, Patronov A, Slavov SH, Vanhoecke BW, Katritzky AR, Bracke ME, Stevens CV.. (2015) 4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model., 101 [PMID:26204510] [10.1016/j.ejmech.2015.06.029] |
| 124. Fiorino F, Ciano A, Magli E, Severino B, Corvino A, Perissutti E, Frecentese F, Di Vaio P, Izzo AA, Capasso R, Massarelli P, Nencini C, Rossi I, Kędzierska E, Orzelska-Gòrka J, Bielenica A, Santagada V, Caliendo G.. (2016) Synthesis, in vitro and in vivo pharmacological evaluation of serotoninergic ligands containing an isonicotinic nucleus., 110 [PMID:26820556] [10.1016/j.ejmech.2016.01.021] |
| 125. WHO Anatomical Therapeutic Chemical Classification, |
| 126. DrugMatrix, [10.6019/CHEMBL3885881] |
| 127. (2016) Quinuclidine derivatives and medicinal compositions containing the same, |
| 128. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development., 118 (2): [PMID:20829430] [10.1093/toxsci/kfq269] |
| 129. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
| 130. Bender AM, Weiner RL, Luscombe VB, Cho HP, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW.. (2017) Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype., 27 (11): [PMID:28427812] [10.1016/j.bmcl.2017.04.009] |
| 131. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 132. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 133. Pegoli A, She X, Wifling D, Hübner H, Bernhardt G, Gmeiner P, Keller M.. (2017) Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M2 Muscarinic Acetylcholine Receptor., 60 (8): [PMID:28388054] [10.1021/acs.jmedchem.6b01892] |
| 134. Zhang Y, Wang Y, He C, Liu X, Lu Y, Chen T, Pan Q, Xiong J, She M, Tu Z, Qin X, Li M, Tortorella MD, Talley JJ.. (2017) Pentafluorosulfanyl-Substituted Benzopyran Analogues As New Cyclooxygenase-2 Inhibitors with Excellent Pharmacokinetics and Efficacy in Blocking Inflammation., 60 (10): [PMID:28475316] [10.1021/acs.jmedchem.6b01484] |
| 135. Bender AM, Weiner RL, Luscombe VB, Ajmera S, Cho HP, Chang S, Zhan X, Rodriguez AL, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW.. (2017) Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists., 27 (15): [PMID:28633897] [10.1016/j.bmcl.2017.05.042] |
| 136. Łażewska D, Kaleta M, Hagenow S, Mogilski S, Latacz G, Karcz T, Lubelska A, Honkisz E, Handzlik J, Reiner D, Satała G, Filipek B, Stark H, Kieć-Kononowicz K.. (2018) Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation., 26 (9): [PMID:29681486] [10.1016/j.bmc.2018.04.023] |
| 137. Szczepańska K, Karcz T, Mogilski S, Siwek A, Kuder KJ, Latacz G, Kubacka M, Hagenow S, Lubelska A, Olejarz A, Kotańska M, Sadek B, Stark H, Kieć-Kononowicz K.. (2018) Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands., 152 [PMID:29723785] [10.1016/j.ejmech.2018.04.043] |
| 138. Fiorino F, Magli E, Kędzierska E, Ciano A, Corvino A, Severino B, Perissutti E, Frecentese F, Di Vaio P, Saccone I, Izzo AA, Capasso R, Massarelli P, Rossi I, Orzelska-Gòrka J, Kotlińska JH, Santagada V, Caliendo G.. (2017) New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: Synthesis, in vitro and in vivo pharmacological evaluation., 25 (20): [PMID:28943244] [10.1016/j.bmc.2017.09.018] |
| 139. Unpublished dataset, |
| 140. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 141. Lee NR, Gujarathi S, Bommagani S, Siripurapu K, Zheng G, Dwoskin LP.. (2019) Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 - M5 muscarinic acetylcholine receptors., 29 (3): [PMID:30554957] [10.1016/j.bmcl.2018.12.022] |
| 142. Pegoli A, Wifling D, Gruber CG, She X, Hübner H, Bernhardt G, Gmeiner P, Keller M.. (2019) Conjugation of Short Peptides to Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Determines M2R Selectivity., 62 (11): [PMID:31074983] [10.1021/acs.jmedchem.8b01967] |
| 143. Łażewska D, Kaleta M, Schwed JS, Karcz T, Mogilski S, Latacz G, Olejarz A, Siwek A, Kubacka M, Lubelska A, Honkisz E, Handzlik J, Filipek B, Stark H, Kieć-Kononowicz K.. (2017) Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H3 receptor ligands., 25 (20): [PMID:28797771] [10.1016/j.bmc.2017.07.058] |
| 144. Rana P, Will Y, Nadanaciva S, Jones LH.. (2016) Development of a cell viability assay to assess drug metabolite structure-toxicity relationships., 26 (16): [PMID:27397500] [10.1016/j.bmcl.2016.06.088] |
| 145. Łażewska D, Mogilski S, Hagenow S, Kuder K, Głuch-Lutwin M, Siwek A, Więcek M, Kaleta M, Seibel U, Buschauer A, Filipek B, Stark H, Kieć-Kononowicz K.. (2019) Alkyl derivatives of 1,3,5-triazine as histamine H4 receptor ligands., 27 (7): [PMID:30792106] [10.1016/j.bmc.2019.02.020] |
| 146. She X, Pegoli A, Gruber CG, Wifling D, Carpenter J, Hübner H, Chen M, Wan J, Bernhardt G, Gmeiner P, Holliday ND, Keller M.. (2020) Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M2 Receptor., 63 (8): [PMID:32233403] [10.1021/acs.jmedchem.9b02172] |
| 147. Del Bello F, Bonifazi A, Giorgioni G, Piergentili A, Sabbieti MG, Agas D, Dell'Aera M, Matucci R, Górecki M, Pescitelli G, Vistoli G, Quaglia W.. (2020) Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus., 63 (11): [PMID:32374602] [10.1021/acs.jmedchem.9b02100] |
| 148. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 149. Lin SX,Curtis MA,Sperry J. (2020) Pyridine alkaloids with activity in the central nervous system., 28 (24): [PMID:33120080] [10.1016/j.bmc.2020.115820] |
| 150. Chan ZY, Krishnan P, Modaresi SM, Hii LW, Mai CW, Lim WM, Leong CO, Low YY, Wong SK, Yong KT, Leong AZ, Lee MK, Ting KN, Lim KH.. (2021) Monomeric, Dimeric, and Trimeric Tropane Alkaloids from Pellacalyx saccardianus., 84 (8.0): [PMID:34342431] [10.1021/acs.jnatprod.1c00374] |
| 151. (2022) Tm Shift (DSF) assay results for EUbOPEN Chemogenomis Library 2 (Incucyte), [10.6019/CHEMBL5058564] |
| 152. EUbOPEN. (2022) EUbOPEN Chemogenomics Library wave 2 - DSF, [10.6019/CHEMBL5060014] |
| 153. EUbOPEN. (2023) GPCR results for EUbOPEN Chemogenomics Library 3, [10.6019/CHEMBL5209801] |
| 154. Puhl AC, Fernandes RS, Godoy AS, Gil LHVG, Oliva G, Ekins S.. (2023) The protein disulfide isomerase inhibitor 3-methyltoxoflavin inhibits Chikungunya virus., 83 [PMID:36940609] [10.1016/j.bmc.2023.117239] |
| 155. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
| 156. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL.. (2019) Mapping human microbiome drug metabolism by gut bacteria and their genes., 570 (7762): [PMID:31158845] [10.1038/s41586-019-1291-3] |
